« Back
Home /
Raltegravir potassium

Raltegravir potassium

€30.00

Excl. VAT

Item no.	HY-10353A-5mg
Manufacturer	MedChem Express
CASRN	871038-72-1
Amount	5 mg
Category	Food Safety Hormones Neuroscience Aging & Neurological Disorders Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.96
Formula	C20H20FKN6O5
Citations	Plant Biosyst. 2018, 1-8. PLoS One. 2018 Mar 30;13(3):e0195168. Bioorg Med Chem. 2019 Sep 1;27(17):3836-3845. Clin Drug Investig. 2019 Mar;39(3):285-299. J Infect Dis. 2022 Sep 19;jiac386. J Mol Biol. 2022 Feb 22;167507. J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692. J Virol. 2017 Jan 18;91(3). pii: e02152-16. Life Sci. 9 September 2022, 120948. Molecules. 2022 Dec 12;27(24):8829. PeerJ Physical Chemistry. 2019, 1:e6. Pharmaceuticals. 2023 Aug 8, 16(8), 1118. Phytomedicine. 2016 Nov 15;23(12):1383-1391. SSRN. 2023 Mar 30. Virol Sin. 2023 May 10;S1995-820X(23)00054-8. Virology. 2023 Jun 21. Viruses. 2021 Jan 18;13(1):E131. [1]Hare, S., et al., Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A, 2010. 107(46): p. 20057-62. [2]Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72. [3]Lewis, M.G., et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology, 2010. 7: p. 21. [4]Hicks C, et al. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9 [5]Moss DM, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012 Jun;56(6):3020-6
Smiles	O=C(C(N=C(C(NC(C1=NN=C(C)O1)=O)(C)C)N2C)=C(O[K])C2=O)NCC3=CC=C(F)C=C3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	MK 0518 (potassium)
Available
Product Description	Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-anti-virus
Molecular Weight	482.51
Clinical Information	Launched
Solubility	DMSO : 20.83 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O : 25 mg/mL (ultrasonic)
Isoform	HIV-1; HIV-2
Pathway	Anti-infection; Metabolic Enzyme/Protease
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10353A-5mg-safety-datasheet.pdf